EDIT Editas Medicine Inc

Price (delayed)

$12.23

Market cap

$839.48M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.73

Enterprise value

$651.76M

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a ...

Highlights

Editas Medicine's quick ratio has increased by 37% YoY and by 26% QoQ

The debt has contracted by 20% YoY and by 12% from the previous quarter

Editas Medicine's net income has decreased by 38% YoY but it has increased by 3.2% QoQ

EDIT's EPS is down by 24% year-on-year but it is up by 4.2% since the previous quarter

The revenue has dropped by 72% year-on-year

Editas Medicine's gross profit has plunged by 72% YoY

Sector: Healthcare

Industry: Biotechnology

Website: http://www.editasmedicine.com

Peers: MRVI MGTX NBIX

Key stats

What are the main financial stats of EDIT

Market

Shares outstanding

68.64M

Market cap

$839.48M

Enterprise value

$651.76M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

1.63

Price to sales (P/S)

32.44

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

25.25

Earnings

Revenue

$25.82M

EBIT

-$188.97M

EBITDA

-$183.52M

Free cash flow

-$173.69M

Per share

EPS

-$2.73

Free cash flow per share

-$2.54

Book value per share

$7.48

Revenue per share

$0.38

TBVPS

$9.1

Balance sheet

Total assets

$623.11M

Total liabilities

$110.35M

Debt

$23.16M

Equity

$512.76M

Working capital

$460.53M

Liquidity

Debt to equity

0.05

Current ratio

13.62

Quick ratio

13.42

Net debt/EBITDA

1.02

Margins

EBITDA margin

-710.9%

Gross margin

100%

Net margin

-721.6%

Operating margin

-724.4%

Efficiency

Return on assets

-26.9%

Return on equity

-32.9%

Return on invested capital

-45.3%

Return on capital employed

-32.2%

Return on sales

-732%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

EDIT stock price

How has the Editas Medicine stock price performed over time

Intraday

-1.77%

1 week

1.16%

1 month

4.71%

1 year

-73.47%

YTD

-53.94%

QTD

-35.7%

Financial performance

How have Editas Medicine's revenue and profit performed over time

Revenue

$25.82M

Gross profit

$25.82M

Operating income

-$187.01M

Net income

-$186.29M

Gross margin

100%

Net margin

-721.6%

The revenue has dropped by 72% year-on-year

Editas Medicine's gross profit has plunged by 72% YoY

Editas Medicine's net income has decreased by 38% YoY but it has increased by 3.2% QoQ

EDIT's operating income is down by 29% year-on-year but it is up by 3.2% since the previous quarter

Growth

What is Editas Medicine's growth rate over time

Valuation

What is Editas Medicine stock price valuation

P/E

N/A

P/B

1.63

P/S

32.44

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

25.25

EDIT's EPS is down by 24% year-on-year but it is up by 4.2% since the previous quarter

EDIT's P/B is 69% below its 5-year quarterly average of 5.4 and 60% below its last 4 quarters average of 4.2

EDIT's equity is down by 20% year-on-year and by 7% since the previous quarter

The revenue has dropped by 72% year-on-year

The P/S is 53% less than the last 4 quarters average of 70.6 and 48% less than the 5-year quarterly average of 63.4

Efficiency

How efficient is Editas Medicine business performance

Editas Medicine's ROA has decreased by 30% YoY and by 2.3% from the previous quarter

The ROE has decreased by 16% YoY and by 2.2% from the previous quarter

EDIT's return on sales is up by 4% since the previous quarter

EDIT's return on invested capital is up by 3.4% since the previous quarter

Dividends

What is EDIT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for EDIT.

Financial health

How did Editas Medicine financials performed over time

The current ratio has grown by 38% YoY and by 26% from the previous quarter

Editas Medicine's quick ratio has increased by 37% YoY and by 26% QoQ

The debt is 95% less than the equity

EDIT's equity is down by 20% year-on-year and by 7% since the previous quarter

The debt has contracted by 20% YoY and by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.